biopharmaceutical
- Business
Curia to Acquire US-Based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics
Albany, N.Y., United States: Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced it has entered…
Read More » - Technology
Bosch Power Tools Launches Affordability Campaign to Improve Ownership Cost of Its Quality Tools for Its User
Albany, N.Y., United States: Bosch Power Tools has embarked on a high impact campaign by rationalizing the prices of spares…
Read More » - Business Wire
AMRI Becomes Curia
New Brand Reinforces Commitment to Ongoing Expansion of Expertise, Capabilities and Contributions to Health Care ALBANY, N.Y.–(BUSINESS WIRE)–#AMRI–Albany Molecular Research,…
Read More » - Business Wire
Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2020
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F…
Read More » - Business Wire
Ferring and Rebiotix Present Positive Interim Phase 3 Results From Open-Label Study of Investigational Microbiota-Based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW)
Interim analysis of the Phase 3 PUNCH™ CD3-Open-Label Study (OLS) showed positive efficacy and consistent safety with RBX2660 for up…
Read More » - Business Wire
Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results
− Takeda’s dengue vaccine candidate (TAK-003) prevented 83.6% of hospitalizations and 62.0% of dengue illness overall, with no identified important…
Read More » - Business
Goldman Sachs Invests in Aragen Life Sciences
Hyderabad, India: Aragen Life Sciences (“Aragen”), formerly known as GVK Biosciences and a leading contract research organization (CRO), announced today…
Read More » - India
Government Supports Augmentation of Manufacturing Capacity for COVAXIN production under Mission COVID Suraksha
Under Atmanirbhar Bharat 3.0 Mission COVID Suraksha was announced by the Government of India, to accelerate the development and production…
Read More » - Technology
Wipro Partners with Transcell Oncologics to Transform Vaccine Safety Assessment
Use of the Wipro HOLMES® Augmented Intelligence platform will lead to safer vaccines and faster rollout to patients NEW YORK…
Read More » - Business Wire
Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer
− Prescription Drug User Fee Act (PDUFA) Target Action Date Set for October 26, 2021 CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS…
Read More » - World
LintonPharm Announces Authorization from China Health Authority (NMPA) to Proceed with a Phase 1/2 Trial Evaluating Catumaxomab for the treatment of Non-Muscle Invasive Bladder Cancer
Guangzhou, China: LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific…
Read More » - Business
Takeda Completes Sale of Its Japan Consumer Health Care Business Unit to Blackstone
Osaka, Japan: Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of Takeda Consumer…
Read More » -
Takeda Completes Sale of Select OTC and Non-Core Assets to Orifarm
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of…
Read More » - Technology
Alvotech Disputes AbbVie’s Recent Allegations
Reykjavik, Iceland: Alvotech strongly disputes AbbVie’s allegations of wrongdoing relating to AVT02, Alvotech’s proposed biosimilar to HUMIRA® (adalimumab). Alvotech will…
Read More » - Business Wire
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
Strong R&D commitment to developing therapeutics against SARS-CoV-2 virus Overall R&D investment up 7% to 3.7 billion EUR in 2020…
Read More » - Business Wire
PCI Pharma Broadens Clinical Trial Service Offerings at Berlin Facility, Bringing Worldwide Access to Clients in the European Union
Cold Storage and Distribution Expansions Support Vaccine and Biologics Supply Chain, Keep Pace With Global Industry Trends PHILADELPHIA–(BUSINESS WIRE)–PCI Pharma…
Read More » - Health
Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine
Osaka, Japan: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and…
Read More » - Business
Takeda’s Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade1
Osaka, Japan & Cambridge, Mass., United States: Aiming for Revenues of JPY 1 Trillion (approximately US$9 Billion2) by FY2030 Double-Digit…
Read More » - Health
Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
Osaka, Japan & New York, United States: − Ovid eligible to receive up to $856M in payments, including a $196M…
Read More » - Technology
Yokogawa and ICQ Consultants Enter Into Partnership Agreement for Biopharmaceutical Business
TOKYO, Japan & Southborough, Mass., United States: Yokogawa Electric Corporation (TOKYO:6841) (Yokogawa) and Integrated Commissioning and Qualification Consultants, Corp. (ICQ…
Read More » - Business
Takeda Completes Sale of TachoSil® to Corza Health
Osaka, Japan: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has completed the previously announced sale of TachoSil® Fibrin Sealant Patch…
Read More » -
Takeda Completes Sale of Select OTC and Non-Core Assets to Hypera Pharma
Osaka, Japan: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of…
Read More » - Business
Takeda to Present at The 39th Annual J.P. Morgan Healthcare Conference
Osaka, Japan & Cambridge, Mass., United States: Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) will present virtually at the…
Read More » - Health
Rhizen Pharmaceuticals SA Announces Presentation of the Interim Results of the Phase I/II study of Tenalisib (RP6530) in Combination with Romidepsin in Relapsed/Refractory T-cell Lymphoma at American Society of Hematology (ASH) annual meeting, 2020
LA CHAUX DU FONDS, Switzerland: Rhizen announces presentation of interim data from its Tenalisib + Romidepsin combination study in patients…
Read More » - India
Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 2020
LA CHAUX DU FONDS, Switzerland: Rhizen announces the approval of its IND by USFDA for its oral DHODH inhibitor for…
Read More » - United States
PCI Pharma Services Announces the Closing of the Majority Stake Acquisition by Kohlberg and Mubadala
Philadelphia, United States: PCI Pharma Services (“PCI” or “the Company”), a leading pharmaceutical and biopharmaceutical global supply-chain solutions provider, today…
Read More » - United States
Humanigen Australia Proprietary Limited Established to Facilitate Asia-Pacific Growth Plans
Burlingame, Calif., United States: New Humanigen entity in Australia creates focused opportunity for partnering, regional clinical trials and market access…
Read More » - Health
Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual Meeting
Osaka, Japan & Cambridge, Mass., United States: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present 22 company-sponsored…
Read More » - United States
VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan
St. Gallen, Switzerland & Mountain View, Calif., United States: Companies have completed the EU regulatory application for marketing approval of…
Read More » - Business
Takeda FY2020 H1 Results Demonstrate Portfolio Resilience; Confirms Full-Year Management Guidance & Raises Forecasts for Free Cash Flow, Reported OP & Reported EPS
Osaka, Japan: FY2020 H1 results driven by growth of global brands (e.g. Entyvio +25.8% YOY, TAKHZYRO +45.5% YOY, NINLARO +…
Read More »
- 1
- 2